Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Benitec Biopharma Stock Quote

Benitec Biopharma (NASDAQ: BNTC)

$6.66
(-0.8%)
-$0.06
Price as of April 25, 2024, 11:48 a.m. ET

Benitec Biopharma Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
BNTC +79.76% -98.48% -56.67% -100%
S&P +24.56% +72.51% +11.52% +159%

Benitec Biopharma Company Info

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.